M
Massive Bio
Biotech & Life Sciences · Istanbul, Türkiye · Founded 2014
AI powered oncology platform that connects patients to clinical trials while enabling pharma to get access to patients MoreLess
Massive Bio operates an AI-powered platform that connects cancer patients and their oncologists to clinical trials. The company's service is designed to streamline the search process for treatment options by using machine learning and artificial intelligence to analyze a patient's medical records and identify suitable clinical trials. This service is provided free of charge to patients. The business model appears to be centered around providing pharmaceutical companies with access to a pre-screened pool of patients for their clinical trials, thus accelerating patient recruitment. The company serves individual cancer patients and their doctors, as well as pharmaceutical companies conducting oncology research. The market is the global oncology clinical trial industry. By combining technology with physician expertise, the company aims to improve patient access to next-generation cancer therapies. The platform functions as a clinical trial matching system, aiming to reduce the time and complexity involved in finding appropriate trials for cancer patients. This approach also provides value to biopharmaceutical companies by optimizing their patient recruitment process for clinical studies. The company has stated its commitment to ensuring patients have equal access to advanced therapies and clinical trials, regardless of their location or financial situation.
Keywords: oncology, clinical trials, AI, patient recruitment, cancer treatment, precision medicine, health-tech, biopharmaceutical, data analysis, medical records
Company overview
Massive Bio company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2014
- Headquarters
- Istanbul, Türkiye
- Employees
- 100
- Open positions
- None listed
- Dealroom signal
- 69.1
- Investment activity
- 1 companies · latest Aug 2026
- Capital deployed
- —
- Preferred round
- GROWTH EQUITY NON VC
Valuation & funding
Massive Bio funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Dec 2022 | $17M | $66M | International Finance Corporation · ImpactAssets · Toyota Financial Services · Kenan Turnacioğlu | ↗ |
| EARLY VC✓Equity / VC | Jun 2022 | $9M | $36M | German Investment Corporation · Revo Capital · Kenan Turnacioğlu | ↗ |
| SEED✓Equity / VC | Nov 2020 | $2.6M | $10M | Revo Capital · Cavendish Impact Capital | — |
| SEED✓Equity / VC | May 2019 | $0 | — | UL Ventures | — |
| EARLY VC✓Equity / VC | Jul 2018 | $0 | — | UL Ventures | — |
| SEED✓Equity / VC | Jul 2016 | Undisclosed | — | ||
| CONVERTIBLE✓Equity / VC | Apr 2015 | 500 Global | — |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $8.3M | 0% | 99 |
| 2025 | $8.3M | 0% | 102 |
| 2024 | $8.3M | 0% | 102 |
| 2023 | $8.3M | +205.6% | 86 |
| 2022 | $2.7M | 0% | 49 |
| 2021 | $2.7M | +80% | 33 |
| 2020 | $1.5M | — | 19 |
Growth signals
Massive Bio website traffic
Latest recorded traffic for Massive Bio is 280K monthly website visits, up 40% over the last three months. Massive Bio's team declined 2% over the past year.
Comparisons
Massive Bio compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Massive Bio investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Massive Bio's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Massive Bio has talent and traffic
team presence
In the news
Latest news about Massive Bio
Recent press, funding announcements, and product moves mentioning Massive Bio — open to read from the original sources.
Market sentiment
What the market is saying about Massive Bio
An AI-synthesized read of the highest-engagement posts about Massive Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Massive Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.